How Zoetis Makes its Money: Revenue Breakdown
A breakdown of Zoetis (ZTS) financials. See how Zoetis makes money from Companion Animal Products, Livestock Products using their 2024 annual report.
How Does Zoetis Make its Money?
Zoetis is the world’s largest animal health company, spun off from Pfizer in 2013. The company discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, and technology for companion animals (pets) and livestock. Zoetis benefits from powerful secular trends: pet humanization driving increased spending on veterinary care, and rising global protein demand requiring healthier and more productive livestock. The company’s blockbuster parasiticide Simparica Trio for dogs and its growing diagnostics portfolio are key growth engines.
Zoetis (ZTS) Business Model
Zoetis Competitors
Zoetis’s key competitors and comparable public companies in the animal health sector include Eli Lilly, Pfizer, and Johnson & Johnson. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Zoetis stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Companion Animal Products | $5,600 | $5,000 | +12.0% |
| Livestock Products | $3,300 | $3,200 | +3.1% |
| Total Revenue | $9,100 | $8,500 | +7.1% |
Companion Animal Products — 62% of Revenue
Revenue from medicines, vaccines, diagnostics, and technology products for pets — primarily dogs and cats. Revenue grew 12.0% to $5.6 billion in 2024, driven by the blockbuster Simparica franchise, growing diagnostics adoption, and the launch of new products. Zoetis’ companion animal portfolio includes parasiticides (Simparica Trio for dogs — a combination flea, tick, and heartworm product that has rapidly taken market share), anti-inflammatory pain treatments (Librela/Solensia — first-in-class monoclonal antibodies for osteoarthritis pain in dogs and cats), vaccines (core canine and feline vaccines), dermatology (Apoquel and Cytopoint for allergic dermatitis), diagnostics equipment and consumables (Vetscan point-of-care analyzers, reference lab services), and digital technology platforms for veterinary practices.
The companion animal business benefits from a powerful secular tailwind: pet humanization. Pet owners increasingly view their dogs and cats as family members and are willing to spend significantly more on veterinary care, prescription medicines, diagnostics, and preventive health than previous generations. US pet industry spending has grown 6-8% annually for over two decades with virtually no cyclical downturns — even during the 2008-2009 recession, pet spending barely declined. This makes Zoetis’ companion animal franchise one of the most recession-resistant consumer health businesses in existence.
Simparica Trio is the centerpiece growth product — launched in 2020, it has rapidly captured market share from Boehringer Ingelheim’s NexGard and Merck’s Bravecto by offering three-way protection (fleas + ticks + heartworm) in a single monthly chew. Librela (for dogs) and Solensia (for cats) represent a potentially transformative growth platform — they are the first monoclonal antibody therapies approved for animals, providing long-lasting pain relief for osteoarthritis (the most common chronic condition in aging pets) with monthly injections administered at the veterinary clinic.
Livestock Products — 36% of Revenue
Revenue from medicines, vaccines, and health products for cattle, poultry, swine, fish, and sheep. Revenue grew 3.1% to $3.3 billion in 2024. Zoetis’ livestock portfolio includes cattle vaccines (for respiratory, reproductive, and clostridial diseases), poultry vaccines and health products (for avian influenza, Newcastle disease, coccidiosis), swine products (for porcine reproductive and respiratory syndrome, mycoplasma), aquaculture vaccines (for fish farming — Atlantic salmon, tilapia), and parasiticides for cattle and sheep (pour-on and injectable dewormers).
The livestock business is driven by global protein demand — as emerging market populations grow wealthier, they consume more animal protein (beef, chicken, pork, fish), which drives demand for livestock health products. The swine and poultry segments are particularly sensitive to disease outbreaks (African swine fever, avian influenza), which can simultaneously reduce herds (lowering demand) and increase urgency for vaccination and treatment. Livestock represents a stable base business with lower growth than companion animal but significant scale and cash flow generation.
Zoetis (ZTS) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $9,100 | $8,500 |
| Cost of Revenue | $2,800 | $2,700 |
| Gross Profit | $6,300 | $5,800 |
| Operating Expenses | $3,000 | $2,800 |
| Operating Income | $3,300 | $3,000 |
| Net Income | $2,700 | $2,300 |
All values in millions USD unless otherwise stated.
Financial data sourced from Zoetis SEC Filings.
Zoetis (ZTS) Key Financial Metrics
- Gross Margin: 69.2%
- Operating Margin: 36.3%
- Revenue Growth: 7.1%
Is Zoetis Profitable?
Yes, Zoetis is exceptionally profitable with margins that rival pharmaceutical companies. The 69.2% gross margin reflects the proprietary nature of Zoetis’ products — prescription veterinary medicines, vaccines, and diagnostics have limited generic competition (the animal health regulatory pathway for generics is less established than human pharma), long product life cycles, and strong brand loyalty among veterinarians who prescribe them. The 36.3% operating margin expanded from the prior year as revenue growth outpaced operating expense increases. Net income grew 17.4% to $2.7 billion on 7.1% revenue growth, demonstrating meaningful operating leverage. Zoetis’ business model combines pharmaceutical-like margins with consumer staples-like demand resilience — pet owners consistently spend on their animals’ health regardless of economic conditions. Free cash flow is robust and deployed through steady dividends and share buybacks.
Zoetis (ZTS): What to Watch
- Simparica franchise growth and competitive dynamics — Simparica Trio is Zoetis’ largest growth driver. Market share trajectory versus NexGard (Boehringer Ingelheim) and Bravecto (Merck Animal Health), plus the launch of next-generation formulations, determines the parasiticide franchise’s Growth.
- Librela/Solensia monoclonal antibody adoption — These first-in-class osteoarthritis pain treatments represent a potentially large new product category. Veterinarian adoption rates, patient compliance with monthly injections, and expansion into additional pain indications drive the growth opportunity.
- Diagnostics platform expansion — Zoetis is building a comprehensive point-of-care diagnostics business (Vetscan analyzers, reference lab services) to compete with IDEXX Laboratories. Diagnostics represent a high-margin recurring revenue stream with significant cross-sell opportunity to existing pharmaceutical customers.
- Pet spending trends and veterinary visit frequency — The secular tailwind of pet humanization drives Zoetis’ companion animal business. Changes in pet ownership rates, veterinary visit frequency, and willingness to spend on premium treatments all affect growth.
- Livestock disease outbreak dynamics — Avian influenza, African swine fever, and other livestock diseases create demand volatility. Outbreaks increase vaccination demand but can simultaneously reduce herd sizes, creating mixed near-term impacts.
Zoetis (ZTS) Financial Summary
Zoetis is the world’s largest animal health company, operating Companion Animal Products (62%, +12.0%) and Livestock Products (36%, +3.1%). Revenue grew 7.1% to $9.1 billion in 2024 with net income growing 17.4% to $2.7 billion. The 69.2% gross margin and 36.3% operating margin reflect proprietary veterinary medicines with limited generic competition and strong brand loyalty. The growth thesis is the confluence of pet humanization (driving companion animal spending regardless of economic cycles), the Simparica Trio franchise capturing parasiticide market share, the Librela/Solensia monoclonal antibody platform opening a new treatment category, and growing diagnostics revenue.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.